Company: CRAC
Filing Date: 2025-10-20
Form Type: POS462C
Source: 0001213900-25-100119
Chunk: 170

Company: Crown Reserve Acquisition Corp. I
Filing Date: 2025-10-20
Form: POS462C
Chunk 170
---
. Oceantech Acquisitions I Corp. (“Oceantech”) extended the period of time it had to consummate its initial business combination by an aggregate of 30 months. On June3, 2024, Oceantech requested its registration statement be withdrawn effective immediately and announced its termination of the merger agreement for its initial business combination and its liquidation. •Aspire Biopharma Inc. (NASDAQ: ASBP), pre -initialbusiness combination: Powerup Acquisitions Corp. (NASDAQ: PWUP) — Mr. Patel served as a board advisor. Mr. Doshi served as a director from August 2023 until the completion of its initial business combination in February 2025. On February17, 2025, PowerUp Acquisition Corp. (“New Aspire”), consummated the initial business combination, pursuant to that certain Agreement and Plan of Merger, dated August26, 2024, as amended by an Amendment Agreement dated September5, 2024 and a Second Amendment Agreement dated October9, 2024, by and among the New Aspire, PowerUp Merger Sub II, Inc., a Delaware corporation and wholly owned subsidiary of PowerUp, SRIRAMA Associates, LLC, a Delaware limited liability company, Stephen Quesenberry, in the capacity as the seller representative, and Aspire Biopharma, Inc., a Puerto Rico corporation. New Aspire held a shareholder vote to amend its amended and restated memorandum and articles of association to extend the time that the company had to consummate an initial business combination. Upon closing the agreement, “PowerUp Acquisition Corp.” changed its name to “Aspire Biopharma Holdings, Inc.” Prior to the closing of the business combination, certain New Aspire public shareholders exercised their right to redeem certain of their outstanding shares for cash, resulting in the redemption of 507,631shares of the New Aspire Class A common stock outstanding prior to the business combination for an aggregate payment of $5,882,859. •Aesther Healthcare Acquisition Corp. (n/k/a Ocean Biomedical, Inc. (OTC: OCEA)) — Mr. Patel served as a board advisor. Mr. Peterson served as a director from June 2021 until the completion of its initial business combination in February 2023. Mr. Peterson served as a director of the post -combinationcompany until his voluntary resignation on July31, 2025. Mr. Fell served as a director from June 2021 until the completion